9
60
19
↑9
↓60
—19
Evidence suggests Melatonin maydecreaseIbs symptoms.
80 studies (88 claims)
Moderate consensus
Typical effective dose 5 (3–20) mgacross 30 dosed studies
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| sublingual melatonin 3 mg | Decreases - will result in a decrease | post-concussion syndrome symptoms | Human | youths with mild traumatic brain injury | Sublingual melatonin 3 mg and 10 mg, administered daily. | A double-blind, placebo-controlled intervention trial of 3 and 10 mg sublingual melatonin for post-concussion syndrome in youths (PLAYGAME): study protocol for a randomized controlled trial.cited 33× |
| sublingual melatonin 10 mg | Decreases - will result in a decrease | post-concussion syndrome symptoms | Human | youths with mild traumatic brain injury | Sublingual melatonin 3 mg and 10 mg, administered daily. | A double-blind, placebo-controlled intervention trial of 3 and 10 mg sublingual melatonin for post-concussion syndrome in youths (PLAYGAME): study protocol for a randomized controlled trial.cited 33× |
| melatonin 10 mg per day | Increases - Significant improvements | autonomic symptoms | Human | the patient | 10 mg per day | Short-Lasting Unilateral Neuralgiform Headache with Conjunctival Injection and Tearing Secondary to Head and Neck Trauma: Literature Review and Case Report.cited 5× |
| melatonin analogues (ramelteon, agomelatine, TIK-301, Neu-P11 and tasimelteon) | Decreases - alleviate | depressive symptoms | Human | depressed subjects | Not specified | Circadian Rhythm and Melatonin in the Treatment of Depression.cited 64× |
| melatonin 20 mg | No effect - did not prevent or significantly improve | fatigue and other symptoms | Human | patients with early stage breast cancer undergoing RT | 20 mg orally, starting the night before radiotherapy initiation until 2 weeks post-radiotherapy. | Melatonin Supplementation for Cancer-Related Fatigue in Patients With Early Stage Breast Cancer Receiving Radiotherapy: A Double-Blind Placebo-Controlled Trial.cited 6× |
| melatonin | Decreases - neuroprotective effect | adverse effects of ACBC on cognitive function, sleep quality and depressive symptoms | Human | women with breast cancer | 20mg of melatonin before and during the first cycle of chemotherapy. | Clinical impact of melatonin on breast cancer patients undergoing chemotherapy; effects on cognition, sleep and depressive symptoms: A randomized, double-blind, placebo-controlled trial.cited 69× |
| melatonin | Decreases - has a preventive effect | anxiety symptoms | Human | patients after acute coronary syndrome | 25 mg melatonin. | The effect of MElatonin on Depressive symptoms, Anxiety, CIrcadian and Sleep disturbances in patients after acute coronary syndrome (MEDACIS): study protocol for a randomized controlled trial.cited 16× |
| melatonin | Decreases - has a preventive effect | depressive symptoms | Human | patients after acute coronary syndrome | 25 mg melatonin. | The effect of MElatonin on Depressive symptoms, Anxiety, CIrcadian and Sleep disturbances in patients after acute coronary syndrome (MEDACIS): study protocol for a randomized controlled trial.cited 16× |
| melatonin | No effect - negative studies involving | behavioral symptoms of dementia | Human | older adults in long-term care (LTC) homes | Not specified | Advances in the treatment of psychiatric disorders in long-term care homes.cited 13× |
| melatonin | Decreases - improves | climacteric symptoms | Human | menopausal women | 3 mg and above | Melatonin and the health of menopausal women: A systematic review.cited 16× |
| Melatonin | No effect - appears to have minimal effects in reducing | core ADHD symptoms | Human | children with ADHD | Not available | Nutritional supplements for the treatment of ADHD.cited 23× |
| melatonin | Decreases - reductions in | depressive symptoms | Human | participants with TBI-induced sleep disturbance | — | The Utility of Melatonin for the Treatment of Sleep Disturbance After Traumatic Brain Injury: A Scoping Review.cited 8× |
| melatonin | Decreases - significantly improved | depressive symptoms | Human | hemodialysis patients | 3 mg daily melatonin. | Role of Melatonin as an Adjunctive Treatment for Depression and Cognitive Impairment in Hemodialysis Patients: A Randomized, Double-Blind Clinical Trial. |
| melatonin | Decreases - might immediately be able to prevent | development of severe symptoms | Human | patients with coronavirus | — | Potential Therapeutic Approach of Melatonin against Omicron and Some Other Variants of SARS-CoV-2.cited 9× |
| melatonin | Decreases - positive effect | FM symptoms | Human | FM patients | Not specified | Melatonin in the treatment of fibromyalgia symptoms: A systematic review.cited 20× |
| melatonin | No effect - resulted in no benefits to | general menopause symptoms | Human | menopausal women | 1 mg to 5 mg (varied by study). | Effects of exogenous melatonin on sleep quality and menopausal symptoms in menopausal women: a systematic review and meta-analysis of randomized controlled trials.cited 9× |
| melatonin | Decreases - improved | physical symptoms | Human | menopausal women | 1 mg to 5 mg (varied by study). | Effects of exogenous melatonin on sleep quality and menopausal symptoms in menopausal women: a systematic review and meta-analysis of randomized controlled trials.cited 9× |
| melatonin | Decreases - could be used as an adjuvant treatment | insomnia symptoms | Human | patients during acute phases | 0.125mg (small dose mentioned for chronobiotic action; dose-effect relationship noted for sleep-inducing effects). | The use of melatonin in adult psychiatric disorders: Expert recommendations by the French institute of medical research on sleep (SFRMS).cited 35× |
| melatonin | Decreases - is a possible treatment | painful symptoms | Human | patients with somatoform disorders | 0.125mg (small dose mentioned for chronobiotic action; dose-effect relationship noted for sleep-inducing effects). | The use of melatonin in adult psychiatric disorders: Expert recommendations by the French institute of medical research on sleep (SFRMS).cited 35× |
| melatonin | No effect - assess impact upon | lower urinary tract symptoms (LUTS) | Human | MS patients | 2 mg at bedtime. | Protocol for a randomized, double blind, placebo controlled, crossover trial of Melatonin for treatment of Nocturia in adults with Multiple Sclerosis (MeNiMS).cited 8× |
| melatonin | No effect - evidence for an effect of in improving is not significant | mood symptoms | Human | patients with depressive episodes | Not specified | Melatonin as a treatment for mood disorders: a systematic review.cited 36× |
| melatonin | Decreases - might be a promising therapeutic option in amelioration | MS symptoms | Human | — | Not specified | Targeting Keap1/Nrf2/ARE signaling pathway in multiple sclerosis.cited 67× |
| melatonin | Decreases - exhibits diverse neuroprotective effects | neuropathological symptoms | Human | neurodegenerative and neuropsychiatric conditions (depression, schizophrenia, bipolar disorder, and autism spectrum disorder) | Not specified | Modulation of neural circuits by melatonin in neurodegenerative and neuropsychiatric disorders.cited 7× |
| melatonin | No effect - no difference between intervention and placebo or no treatment | No clinically important improvement in TD symptoms | Human | adults with chronic psychiatric disorders, mostly schizophrenia, and antipsychotic-induced TD | Not specified | Miscellaneous treatments for antipsychotic-induced tardive dyskinesia.cited 19× |
| melatonin (3 mg) | Decreases - beneficial effects on sleep quality are associated with improved | non-motor symptoms | Human | PD patients | 3 mg melatonin daily. | Melatonin on sleep in Parkinson's disease: A randomized double blind placebo controlled trial.cited 5× |
| melatonin (3 mg) | Decreases - favoring melatonin | Non-Motor Symptoms Scale (NMSS) | Human | IPD patients | 3 mg melatonin daily. | Melatonin on sleep in Parkinson's disease: A randomized double blind placebo controlled trial.cited 5× |
| Melatonin (MLT) | Decreases - observed a considerable, dose-dependent alleviation in | NP symptoms | HumanAnimal | mice with spared nerve injury (SNI) NP model | — | Melatonin Induces Analgesic Effects through MT |
| melatonin | Decreases - reducing | opioid withdrawal symptoms | Human | preclinical studies | Not specified | Exploring the association between melatonin and nicotine dependence (Review).cited 1× |
| melatonin supplementation during periods of heightened nicotine cravings | Decreases - may alleviate | withdrawal symptoms | Human | — | Not specified | Exploring the association between melatonin and nicotine dependence (Review).cited 1× |
| melatonin | Increases - induced improvements | other non-motor symptoms | Human | persons with Parkinson's disease (PwP) | Not specified | The multimodal effect of circadian interventions in Parkinson's disease: A narrative review.cited 3× |
| melatonin agonists | Increases - induced improvements | other non-motor symptoms | Human | persons with Parkinson's disease (PwP) | Not specified | The multimodal effect of circadian interventions in Parkinson's disease: A narrative review.cited 3× |
| melatonin | No effect - effect on | other patient-reported symptoms | Human | participants | 25 mg melatonin administered rectally daily. | Effect of melatonin in patients with low anterior resection syndrome (MELLARS): a study protocol for a randomised, placebo-controlled, crossover trial.cited 2× |
| melatonin | No effect - no significant differences | other symptoms | Human | cachectic patients with advanced cancer | 20 mg at night | Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial.cited 72× |
| melatonin | No effect - no evidence that show | PAWS symptoms | Human | — | — | Management of Post-Acute Alcohol Withdrawal: A Mixed-Studies Scoping Review. |
| melatonin | Decreases - efficacy for ameliorating | PD symptoms | Human | animal models of PD employing neurotoxins | — | Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection. |
| melatonin | Decreases - has increasingly been suggested to modulate | PMS symptoms | Human | — | — | Melatonin for premenstrual syndrome: A potential remedy but not ready.cited 5× |
| melatonin treatment | Decreases - can be effective in alleviating | symptoms of PMS | Human | — | — | Melatonin for premenstrual syndrome: A potential remedy but not ready.cited 5× |
| melatonin | No effect - clinical effects | psychiatric symptoms | Human | patients with mild cognitive impairment and AD | Not specified | Role of melatonin in Alzheimer's disease: From preclinical studies to novel melatonin-based therapies.cited 42× |
| melatonin | Decreases - usual choice for symptomatic treatment | RBD symptoms | Human | patients with RBD | Not specified | Current Concepts and Controversies in the Management of REM Sleep Behavior Disorder.cited 17× |
| melatonin | Decreases - ameliorate | RBD symptoms | Human | — | Not specified | The Isolated Form of Rapid Eye Movement Sleep Behavior Disorder: The Upcoming Challenges.cited 4× |
| melatonin | Decreases - reduce | RBD symptoms | Human | most patients | Not specified | Rapid Eye Movement Sleep Behavior Disorder: Management and Prognostic Counseling.cited 2× |
| Melatonin | Decreases - are first-line agents for | RBD symptoms | Human | patients with RBD | Not mentioned | REM Sleep Behavior Disorder and Other REM Parasomnias.cited 1× |
| melatonin | Decreases - prevent severe symptoms | severe symptoms | Human | COVID-19 patients | Not specified | Role of melatonin in the treatment of COVID-19; as an adjuvant through cluster differentiation 147 (CD147).cited 38× |
| melatonin | Decreases - decrease | some symptoms | Human | — | Not available | Influence of the use of atypical antipsychotics in metabolic syndrome.cited 10× |
| melatonin | Decreases - yielded significant results | subjective and objective insomnia symptoms | Human | — | Not specified | An algorithmic approach to the management of insomnia in patients with schizophrenia.cited 6× |
| melatonin | Decreases - may alleviate | subjective symptoms of tinnitus | HumanMolecular | — | 1 to 3 mg daily (modest doses mentioned). | Does melatonin have therapeutic use in tinnitus?cited 3× |
| melatonin | Decreases - is an option for consideration of re-purposing studies | symptoms (insomnia, depression, fatigue, and "brain fog") | Human | "LONG COVID" subjects experiencing insomnia, depression, fatigue, and "brain fog" but not tachycardia | Not specified | "LONG COVID"-A hypothesis for understanding the biological basis and pharmacological treatment strategy.cited 77× |
| melatonin | Decreases - improves symptoms | symptoms in patients with IBS and GERD | Human | patients with IBS and GERD | Not specified | Gut clock: implication of circadian rhythms in the gastrointestinal tract.cited 197× |
| melatonin | Increases - may improve | symptoms of bipolar disorder | Human | patients with bipolar disorder | Not specified | Mitochondrial modulators for bipolar disorder: a pathophysiologically informed paradigm for new drug development. |
| melatonin | Increases - may improve | symptoms of bipolar disorder | Human | patients with bipolar disorder | Not specified | Mitochondrial modulators for bipolar disorder: a pathophysiologically informed paradigm for new drug development. |
| Melatonin | Decreases - could be used as an adjuvant treatment | symptoms of insomnia associated with depression | Human | — | Not specified | Biological rhythms and chronotherapeutics in depression.cited 45× |
| melatonin | No effect - effect | symptoms of irritable bowel syndrome | Human | postmenopausal women | 3 mg fasting and 5 mg at bedtime. | Influence of melatonin on symptoms of irritable bowel syndrome in postmenopausal women.cited 31× |
| melatonin | Decreases - alleviated | symptoms of polyneuropathy | Human | patient | 19 mg/day | The Potential of Integrative Cancer Treatment Using Melatonin and the Challenge of Heterogeneity in Population-Based Studies: A Case Report of Colon Cancer and a Literature Review. |
| Melatonin | Decreases - may be particularly effective at reducing | the signs and symptoms of SARS-CoV-2 infection | Human | — | — | Possible Application of Melatonin in Long COVID.cited 19× |
| melatonin | Decreases - significantly decreased | the symptoms | Human | patients with primary breast cancer | — | Quality-of-life outcomes following topical melatonin application against acute radiation dermatitis in patients with early breast cancer: A double-blind, randomized, placebo-controlled trial.cited 10× |
| exogenous melatonin | Increases - has been shown to improve | sleep structure and psychotic symptoms | Human | schizophrenia | Not specified | Circadian rhythms and clock genes in psychotic disorders. |
| paediatric prolonged-release melatonin (PedPRM) | No effect - will examine the efficacy | PTSD symptoms | Human | children and adolescents with PTSD | Not specified in the abstract. | Protocol MelatoSom-Kids-PTSD: sleep disturbances in children and adolescents with post-traumatic stress disorder (PTSD) - a randomized double-blind placebo-controlled trial to investigate the efficacy of paediatric prolonged-release melatonin. |
| melatonin plus standard care | No effect - no significant difference | symptoms on Day 7 | Human | hospitalized COVID-19 patients | Not specified | Melatonin effects on sleep quality and outcomes of COVID-19 patients: An open-label, randomized, controlled trial.cited 48× |
| melatonin or melatonin-receptor agonists | No effect - pooled effect was not statistically significant | depressive symptoms | Human | — | — | Hypnotic and Melatonin/Melatonin-Receptor Agonist Treatment in Bipolar Disorder: A Systematic Review and Meta-Analysis.cited 14× |
| melatonin or melatonin-receptor agonists | Decreases - largest efficacy signal detected | manic symptoms | Human | — | — | Hypnotic and Melatonin/Melatonin-Receptor Agonist Treatment in Bipolar Disorder: A Systematic Review and Meta-Analysis.cited 14× |
| melatonin or melatonin-receptor agonists | Decreases - suggested beneficial treatment effects | symptoms of sleep disturbance, depression, and mania | Human | patients with BD | — | Hypnotic and Melatonin/Melatonin-Receptor Agonist Treatment in Bipolar Disorder: A Systematic Review and Meta-Analysis.cited 14× |
| adjunctive melatonin | Decreases - demonstrated superior treatment effects versus placebo | manic symptoms during acute mania | Human | — | — | Hypnotic and Melatonin/Melatonin-Receptor Agonist Treatment in Bipolar Disorder: A Systematic Review and Meta-Analysis.cited 14× |
| Melatonin levels | No effect - correlate with | clinical and psychological symptoms of breast cancer | Human | — | Not specified | Circadian Rhythm and Concentration of Melatonin in Breast Cancer Patients.cited 11× |
| bright light and/or melatonin | Decreases - ameliorated | progression of cognitive and noncognitive symptoms | Human | AD patients | Not specified | (Re-)activation of neurons in aging and dementia: lessons from the hypothalamus.cited 19× |
| Melatonin immediate release | Increases - effective, at moderate doses, for improving | symptoms associated with poorly coupled circadian rhythms, including seasonal affective and bipolar disorders | Human | — | Moderate doses (specific amount not stated) for immediate release; prolonged-release and synthetic agonists also mentioned. | Neurobiology, pathophysiology, and treatment of melatonin deficiency and dysfunction.cited 88× |
| hydrodispersible PEA (1,200 mg) and melatonin (0.2 mg) (PEATONIDE®) | Decreases - displayed a reduction | incidence of associated symptoms of migraine attacks | Human | patients with migraine | 1,200 mg PEA and 0.2 mg melatonin. | Fixed combination of palmitoylethanolamide and melatonin in preventive therapy of migraine: results from a randomized clinical trial. |
| omeprazole 20 mg/d plus sublingual melatonin (3 mg/d) | Decreases - declined significantly | Frequency Scale for the Symptoms of gastroesophageal reflux disease score | Human | patients with gastro gastroesophageal reflux disease | 3 mg/day sublingual melatonin + 20 mg/day omeprazole. | Is the Addition of Sublingual Melatonin to Omeprazole Superior to Omeprazole Alone in the Management of Gastroesophageal Reflux Disease Symptoms: A Clinical Trial.cited 1× |
| Melatonin combined with bright light therapy (BLT) | No effect - did not affect | ADHD symptoms | Human | adults with attention-deficit/hyperactivity disorder (ADHD) and delayed sleep phase syndrome (DSPS) | 0.5 mg/day melatonin, with or without 30 minutes of bright light therapy (BLT) between 0700 and 0800 h. | Attention-Deficit/Hyperactivity Disorder and Delayed Sleep Phase Syndrome in Adults: A Randomized Clinical Trial on the Effects of Chronotherapy on Sleep.cited 6× |
| chronotherapy with melatonin | Decreases - reduced | ADHD symptoms | Human | adults with attention-deficit/hyperactivity disorder (ADHD) and delayed sleep phase syndrome (DSPS) | 0.5 mg/day melatonin, with or without 30 minutes of bright light therapy (BLT) between 0700 and 0800 h. | Attention-Deficit/Hyperactivity Disorder and Delayed Sleep Phase Syndrome in Adults: A Randomized Clinical Trial on the Effects of Chronotherapy on Sleep.cited 6× |
| Melatonin treatment | Decreases - was mainly effective in reducing | insomnia symptoms | Human | children with autism spectrum disorders, aged 4-10 years, suffering from sleep onset insomnia and impaired sleep maintenance | Not specified | Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial.cited 152× |
| Short- or longer-term treatment with melatonin PR 2 mg | No effect - was not associated with | dependence, tolerance, rebound insomnia or withdrawal symptoms | Human | — | 2 mg, 1-2 hours before bedtime. | Melatonin prolonged release: in the treatment of insomnia in patients aged ≥55 years.cited 35× |
| Oral melatonin | Decreases - probably reduces | symptoms associated with jet lag syndrome | Human | travelers who cross multiple time zones in a short period of time | Not specified | Is melatonin useful for jet lag?cited 3× |
| Blocking the melatonin system by administrating MT2 receptor antagonist, 4-P-PDOT | Decreases - alleviates | OHSS symptoms | HumanAnimalMolecular | rat OHSS model | — | Melatonin stimulates VEGF expression in human granulosa-lutein cells: A potential mechanism for the pathogenesis of ovarian hyperstimulation syndrome. |
| Melatonin soft gelatin capsule (Danna Pharmaceutical Company) at a dose of 5 mg twice a day for a period of seven days | No effect - investigate the effects | recovery rate of clinical symptoms | Human | severely ill patients with confirmed COVID-19 who are admitted to the Intensive Care Unit (ICU) | 5 mg twice daily (soft gelatin capsule) | Evaluation of the effect of melatonin in patients with COVID-19-induced pneumonia admitted to the Intensive Care Unit: A structured summary of a study protocol for a randomized controlled trial.cited 8× |
| 2 mg per night capsulated sustained-release melatonin (Circadin®) | No effect - no significant difference observed | signs or symptoms of nocturia | Human | patients with nocturia secondary to multiple sclerosis | 2 mg per night (taken at bedtime) of sustained-release melatonin (Circadin®). | Results of a randomized, double blind, placebo controlled, crossover trial of melatonin for treatment of Nocturia in adults with multiple sclerosis (MeNiMS).cited 24× |
| melatonin 1 mg/morning and 3 mg/at bedtime | Increases - resolved | dyspeptic symptoms | Human | 84.3% in Group IIIb | 1 mg in the morning and 3 mg at bedtime. | The value of melatonin supplementation in postmenopausal women with Helicobacter pylori-associated dyspepsia.cited 3× |
| melatonin at a dose of 20 mg | No effect - was not found to improve | other symptoms | Human | patients with advanced cancer | 20 mg orally each night. | Effects of melatonin on physical fatigue and other symptoms in patients with advanced cancer receiving palliative care: A double-blind placebo-controlled crossover trial.cited 32× |
| standard of care plus melatonin at a dose of 3 mg three times daily for 14 d | Decreases - significantly improved | clinical symptoms such as cough, dyspnea, and fatigue | Human | hospitalized patients with confirmed mild to moderate COVID-19 | 3 mg three times daily | Efficacy of a Low Dose of Melatonin as an Adjunctive Therapy in Hospitalized Patients with COVID-19: A Randomized, Double-blind Clinical Trial.cited 58× |
| Melatonin supplementation | Decreases - decrease in | symptoms induced by cancer and cancer treatment | Human | older patients | Not mentioned | Quality of life for older patients with cancer: a review of the evidence supporting melatonin use.cited 7× |
| exogenous melatonin supplementation | No effect - had no effect | insomnia symptoms and severity on the ESS | Human | middle-aged patients with primary insomnia | 3 mg fast-release melatonin daily, taken 1 hour before bedtime. | Efficacy of melatonin for sleep disturbance in middle-aged primary insomnia: a double-blind, randomised clinical trial.cited 28× |
| exogenous melatonin supplementation | No effect - had no effect | insomnia symptoms and severity on the ISI | Human | middle-aged patients with primary insomnia | 3 mg fast-release melatonin daily, taken 1 hour before bedtime. | Efficacy of melatonin for sleep disturbance in middle-aged primary insomnia: a double-blind, randomised clinical trial.cited 28× |
| exogenous melatonin supplementation | No effect - had no effect | insomnia symptoms and severity on the PSQI | Human | middle-aged patients with primary insomnia | 3 mg fast-release melatonin daily, taken 1 hour before bedtime. | Efficacy of melatonin for sleep disturbance in middle-aged primary insomnia: a double-blind, randomised clinical trial.cited 28× |
| melatonin at a moderate dose | Decreases - abating | symptoms after treatment cessation | Human | — | 5 mg melatonin nightly | Moderate dose melatonin for the abatement and treatment of delirium in elderly general medical inpatients: study protocol of a placebo controlled, randomised, double blind trial.cited 5× |
| melatonin at a moderate dose | Decreases - effectively treats | the symptoms of delirium | Human | — | 5 mg melatonin nightly | Moderate dose melatonin for the abatement and treatment of delirium in elderly general medical inpatients: study protocol of a placebo controlled, randomised, double blind trial.cited 5× |
| Melatonin capsules at a dose of 50 mg daily for a period of seven days | Increases - evaluate the efficacy and safety | recovery rate of clinical symptoms | Human | patients with confirmed COVID-19, who are moderately ill | 50 mg daily | Evaluation of the efficacy and safety of Melatonin in moderately ill patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial.cited 17× |
| 3 mg melatonin | No effect - differences | anxiety symptoms | Human | adult participants, aged 50 and older, undergoing elective or semi-elective cardiac surgery | 3 mg melatonin administered daily. | The Healthy Heart-Mind trial: melatonin for prevention of delirium following cardiac surgery: study protocol for a randomized controlled trial.cited 10× |
| 3 mg melatonin | No effect - differences | depressive symptoms | Human | adult participants, aged 50 and older, undergoing elective or semi-elective cardiac surgery | 3 mg melatonin administered daily. | The Healthy Heart-Mind trial: melatonin for prevention of delirium following cardiac surgery: study protocol for a randomized controlled trial.cited 10× |
| prolonged-release (PR) melatonin 2 mg | Decreases - were reduced | Daytime sleepiness and insomnia symptoms | Human | patients with video-polysomnography-confirmed iRBD | 2 mg prolonged-release melatonin, taken 30 minutes before bedtime. | Comparative efficacy of prolonged-release melatonin versus clonazepam for isolated rapid eye movement sleep behavior disorder.cited 8× |
| medications that contain melatonin | Decreases - may have clinical benefits | symptoms of SWD | Human | some patients with SWD | Not specified | Understanding and diagnosing shift work disorder.cited 17× |
| melatonin (Circadin®, Exeltis Healthcare, Spain): 2 mg of melatonin orally before bedtime for 12 weeks | Decreases - evaluate | duration of COVID-19 symptoms | Human | participants receiving melatonin before the infection | 2 mg orally before bedtime. | A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial.cited 29× |
| melatonin add-on treatment with lithium and risperidone | Decreases - leading to significant improvements | manic symptoms | Human | patients with bipolar disorder (BD) experiencing acute manic episodes | 6 mg/day melatonin, 3 mg/day risperidone, and 900 mg/day lithium. | Efficacy of melatonin as an adjunct in the treatment of acute mania: a double-blind and placebo-controlled trial.cited 11× |